Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Pittsburgh, Pennsylvania 15260


Omega-3 fatty acids are a certain kind of fish fat that has recently been shown to have health benefits. This study will examine the effectiveness of fish oil supplementation for reducing the early signs of heart disease risk and for improving mood, impulsivity, and anger levels.

Study summary:

Cardiovascular disease (CVD) is a broad term that includes diseases that affect the heart and blood vessels, including coronary heart disease, heart failure, high blood pressure, and stroke. CVD is the leading cause of death in the United States, resulting in 700,000 deaths each year. Preliminary research has shown that increased consumption of fish, specifically the omega-3 fatty acids found in fish oil, has beneficial effects in people with CVD. Fish oil may also have positive effects on the psychological health and well-being of people with psychiatric disorders. However, more research is needed to confirm the positive physical and psychological effects of fish oil in healthy adults. The purpose of this study is to evaluate the effectiveness of fish oil at reducing CVD risk markers, symptoms of depression and antagonistic disposition, and levels of impulsivity and aggression. The study will also examine whether genetic variations influence the effects of fish oil on markers of inflammation, a characteristic of CVD. This study will enroll healthy adults who habitually consume low quantities of long-chain omega-3 fatty acids. Participants will be randomly assigned to receive either fish oil supplements or placebo on a daily basis for 4 months. Study visits will occur at baseline and Months 2 and 4. At the baseline and Month 4 visits, participants will undergo blood collection; heart rate measurements; and interviews, psychological tests, and questionnaires to assess mood, disposition, impulsivity, and aggression. Additionally, medication adherence will be measured at the Months 2 and 4 study visits and through phone calls from study staff at Week 2 and Month 3.


Inclusion Criteria: - Currently employed at least 25 hours a week, but does not regularly work the third shift (i.e., night shift) - English is primary language - Consumes less than 300 mg/day of long-chain omega-3 fatty acids. Exclusion Criteria: - Serious allergy to fish (e.g., anaphylaxis, bronchospasm, serious skin reaction) - History of atherosclerotic disease (e.g., myocardial infarction) or treatment of angina or claudication (e.g., angioplasty) - Reported history of schizophrenia or bipolar disorder - Long-term hepatitis - Kidney failure - Stroke or other neurological disorder - Lung disease requiring drug treatment - Stage 2 high blood pressure, defined as systolic blood pressure of 160 mm Hg or greater and diastolic blood pressure of 100 mm Hg or greater - Alcohol consumption of more than five drinks per day each week (i.e., more than 35 alcoholic drinks each week) - Pregnant or breastfeeding - Currently taking any cardiovascular, psychotropic, glucocorticoid, lipid-lowering, insulin, or weight loss medications - Currently taking fish oil supplements



Primary Contact:

Principal Investigator
Matthew F. Muldoon, MD, MPH
University of Pittsburgh

Backup Contact:


Location Contact:

Pittsburgh, Pennsylvania 15260
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.